ABT 737

ABT 737 

To Order Contact us: caitlyn@ucb-bioproducts.com

ABT-737

A8193-5.1 10 mM (in 1mL DMSO)
EUR 148
Description: ABT-737 is a novel and potent inhibitor of B-cell lymphoma 2 (BCL-2) family proteins, which are critical for cell survival and overexpressed in many tumor cells, with high affinity towards BCL-XL, BCL-2, and BCL-w but no affinity towards less homologous proteins, such as BCL-B, MCL-1, and A1.

ABT-737

A8193-50 50 mg
EUR 398
Description: ABT-737 is a novel and potent inhibitor of B-cell lymphoma 2 (BCL-2) family proteins, which are critical for cell survival and overexpressed in many tumor cells, with high affinity towards BCL-XL, BCL-2, and BCL-w but no affinity towards less homologous proteins, such as BCL-B, MCL-1, and A1.

ABT-737

A8193-500 500 mg
EUR 1558
Description: ABT-737 is a novel and potent inhibitor of B-cell lymphoma 2 (BCL-2) family proteins, which are critical for cell survival and overexpressed in many tumor cells, with high affinity towards BCL-XL, BCL-2, and BCL-w but no affinity towards less homologous proteins, such as BCL-B, MCL-1, and A1.

ABT-737

A8193-S Evaluation Sample
EUR 81
Description: ABT-737 is a novel and potent inhibitor of B-cell lymphoma 2 (BCL-2) family proteins, which are critical for cell survival and overexpressed in many tumor cells, with high affinity towards BCL-XL, BCL-2, and BCL-w but no affinity towards less homologous proteins, such as BCL-B, MCL-1, and A1.

ABT-737

2463-25
EUR 675

ABT-737

2463-5
EUR 207

ABT

B7737-5.1 10 mM (in 1mL DMSO)
EUR 108

ABT

B7737-50 50 mg
EUR 125

ABT-494

B1947-25
EUR 892

ABT-494

B1947-5
EUR 262

ABT-751

E1KS1165 10mg
EUR 521

ABT-492

E1KS1553 5mg
EUR 1111

ABT-072

HY-101634 10mg
EUR 1399

ABT-670

HY-19483 1mg
EUR 849

ABT-639

HY-19721 100mg
EUR 2943

ABT-239

HY-12195 10mg
EUR 337

ABT-751

HY-13270 50mg
EUR 394

ABT-046

HY-15197 10mM/1mL
EUR 420

Abt-199

abx184638-1g 1 g
EUR 648
  • Shipped within 1-2 weeks.

Abt-869

20-abx182361
  • EUR 1803.00
  • EUR 551.00
  • 100 mg
  • 10 mg
  • Shipped within 1-2 weeks.

ABT-199

A8194-1 1 mg
EUR 131
Description: ABT-199, developed through a structure-based reverse engineering process, is a novel and specific inhibitor of B-cell lymphoma/leukemia 2 (BCL-2) maintaining a sub-nanomolar affinity towards BCL-2 and over three orders of magnitude less affinity towards BCL-XL

ABT-199

A8194-5 5 mg
EUR 270
Description: ABT-199, developed through a structure-based reverse engineering process, is a novel and specific inhibitor of B-cell lymphoma/leukemia 2 (BCL-2) maintaining a sub-nanomolar affinity towards BCL-2 and over three orders of magnitude less affinity towards BCL-XL

ABT-199

A8194-5.1 10 mM (in 1mL DMSO)
EUR 421
Description: ABT-199, developed through a structure-based reverse engineering process, is a novel and specific inhibitor of B-cell lymphoma/leukemia 2 (BCL-2) maintaining a sub-nanomolar affinity towards BCL-2 and over three orders of magnitude less affinity towards BCL-XL

ABT-199

A8194-50 50 mg
EUR 838
Description: ABT-199, developed through a structure-based reverse engineering process, is a novel and specific inhibitor of B-cell lymphoma/leukemia 2 (BCL-2) maintaining a sub-nanomolar affinity towards BCL-2 and over three orders of magnitude less affinity towards BCL-XL

ABT-199

A8194-500 500 mg
EUR 1442
Description: ABT-199, developed through a structure-based reverse engineering process, is a novel and specific inhibitor of B-cell lymphoma/leukemia 2 (BCL-2) maintaining a sub-nanomolar affinity towards BCL-2 and over three orders of magnitude less affinity towards BCL-XL

ABT-199

A8194-S Evaluation Sample
EUR 81
Description: ABT-199, developed through a structure-based reverse engineering process, is a novel and specific inhibitor of B-cell lymphoma/leukemia 2 (BCL-2) maintaining a sub-nanomolar affinity towards BCL-2 and over three orders of magnitude less affinity towards BCL-XL

ABT-869

1615-1
EUR 213

ABT-869

1615-5
EUR 615

ABT-888

1620-1
EUR 218

ABT-888

1620-5
EUR 615

ABT-263

2467-25
EUR 805

ABT-263

2467-5
EUR 262

Zotarolimus(ABT-578)

B4786-25 25 mg
EUR 741
Description: Zotarolimus(ABT-578) is an anti-proliferative drug used exclusively in coronary drug eluting stent [1]. Zotarolimus(ABT-578) is an analogue of rapamycin and an anti-proliferative drug.

Zotarolimus(ABT-578)

B4786-5 5 mg
EUR 347
Description: Zotarolimus(ABT-578) is an anti-proliferative drug used exclusively in coronary drug eluting stent [1]. Zotarolimus(ABT-578) is an analogue of rapamycin and an anti-proliferative drug.

ABT 702 dihydrochloride

B5298-10 10 mg
EUR 412
Description: IC50: 1.7 nM for adenosine kinaseAdenosine (ADO) is an endogenous homeostatic inhibitory neuromodulator that reduces cellular excitability at sites of tissue injury and inflammation.

ABT 702 dihydrochloride

B5298-100 100 mg
EUR 1708
Description: IC50: 1.7 nM for adenosine kinaseAdenosine (ADO) is an endogenous homeostatic inhibitory neuromodulator that reduces cellular excitability at sites of tissue injury and inflammation.

ABT 702 dihydrochloride

B5298-5 5 mg
EUR 276
Description: IC50: 1.7 nM for adenosine kinaseAdenosine (ADO) is an endogenous homeostatic inhibitory neuromodulator that reduces cellular excitability at sites of tissue injury and inflammation.

ABT 702 dihydrochloride

B5298-5.1 10 mM (in 1mL DMSO)
EUR 316
Description: IC50: 1.7 nM for adenosine kinaseAdenosine (ADO) is an endogenous homeostatic inhibitory neuromodulator that reduces cellular excitability at sites of tissue injury and inflammation.

ABT 702 dihydrochloride

B5298-50 50 mg
EUR 1181
Description: IC50: 1.7 nM for adenosine kinaseAdenosine (ADO) is an endogenous homeostatic inhibitory neuromodulator that reduces cellular excitability at sites of tissue injury and inflammation.

ABT 724 trihydrochloride

B6981-10 10 mg
EUR 308
Description: ABT 724 trihydrochloride is a highly selective D4 dopamine agonist [1][2], with an EC50 of 281 nM in increasing the binding activity of GTP?S in CHO cells transfected with human D4 receptors, and of 12.4 nM in increasing Ca2+ influx of HEK-293 cells co-transfected with a G protein (G?q05).

ABT 724 trihydrochloride

B6981-50 50 mg
EUR 1136
Description: ABT 724 trihydrochloride is a highly selective D4 dopamine agonist [1][2], with an EC50 of 281 nM in increasing the binding activity of GTP?S in CHO cells transfected with human D4 receptors, and of 12.4 nM in increasing Ca2+ influx of HEK-293 cells co-transfected with a G protein (G?q05).

ABT-263 (Navitoclax)

E1KS1001 5mg
EUR 521

Linifanib (ABT-869)

E1KS1003 5mg
EUR 521

ABT-888 (Veliparib)

E1KS1004 5mg
EUR 325

Lopinavir(ABT-378)

E1KS1380 10mg
EUR 403

ABT-639 hydrochloride

HY-101616 20mg
EUR 13439

ABT-702 dihydrochloride

HY-103161 100mg
EUR 1313

Paritaprevir(ABT-450)

20-abx184297
  • EUR 1247.00
  • EUR 913.00
  • 10 mg
  • 5 mg
  • Shipped within 1-2 weeks.

Linifanib (ABT-869)

A2949-100 100 mg
EUR 780
Description: Linifanib (ABT-869) is an effective ATP-competitive tyrosine kinase inhibitor against the platelet-derived growth factor (PDGF) receptor and the vascular endothelial growth factor receptor (VEGFR) families, including constitutively active FMS-like receptor tyrosine kinase 3 (FLT3) [1][2].

Linifanib (ABT-869)

A2949-25 25 mg
EUR 328
Description: Linifanib (ABT-869) is an effective ATP-competitive tyrosine kinase inhibitor against the platelet-derived growth factor (PDGF) receptor and the vascular endothelial growth factor receptor (VEGFR) families, including constitutively active FMS-like receptor tyrosine kinase 3 (FLT3) [1][2].

Linifanib (ABT-869)

A2949-5 5 mg
EUR 142
Description: Linifanib (ABT-869) is an effective ATP-competitive tyrosine kinase inhibitor against the platelet-derived growth factor (PDGF) receptor and the vascular endothelial growth factor receptor (VEGFR) families, including constitutively active FMS-like receptor tyrosine kinase 3 (FLT3) [1][2].

Linifanib (ABT-869)

A2949-5.1 10 mM (in 1mL DMSO)
EUR 195
Description: Linifanib (ABT-869) is an effective ATP-competitive tyrosine kinase inhibitor against the platelet-derived growth factor (PDGF) receptor and the vascular endothelial growth factor receptor (VEGFR) families, including constitutively active FMS-like receptor tyrosine kinase 3 (FLT3) [1][2].

ABT-888 (Veliparib)

A3002-10 10 mg
EUR 148
Description: ABT-888, also named as Veliparib, is poly (ADP-ribose) polymerase (PARP) inhibitor and has demonstrated excellent in vivo efficacy in a broad spectrum of preclinical tumor models in combination with a variety of cytotoxic agents.

ABT-888 (Veliparib)

A3002-200 200 mg
EUR 835
Description: ABT-888, also named as Veliparib, is poly (ADP-ribose) polymerase (PARP) inhibitor and has demonstrated excellent in vivo efficacy in a broad spectrum of preclinical tumor models in combination with a variety of cytotoxic agents.

ABT-888 (Veliparib)

A3002-5 5 mg
EUR 125
Description: ABT-888, also named as Veliparib, is poly (ADP-ribose) polymerase (PARP) inhibitor and has demonstrated excellent in vivo efficacy in a broad spectrum of preclinical tumor models in combination with a variety of cytotoxic agents.

ABT-888 (Veliparib)

A3002-5.1 10 mM (in 1mL DMSO)
EUR 160
Description: ABT-888, also named as Veliparib, is poly (ADP-ribose) polymerase (PARP) inhibitor and has demonstrated excellent in vivo efficacy in a broad spectrum of preclinical tumor models in combination with a variety of cytotoxic agents.

ABT-888 (Veliparib)

A3002-50 50 mg
EUR 351
Description: ABT-888, also named as Veliparib, is poly (ADP-ribose) polymerase (PARP) inhibitor and has demonstrated excellent in vivo efficacy in a broad spectrum of preclinical tumor models in combination with a variety of cytotoxic agents.

ABT-888 (Veliparib)

A3002-S Evaluation Sample
EUR 81
Description: ABT-888, also named as Veliparib, is poly (ADP-ribose) polymerase (PARP) inhibitor and has demonstrated excellent in vivo efficacy in a broad spectrum of preclinical tumor models in combination with a variety of cytotoxic agents.

ABT-263 (Navitoclax)

A3007-10 10 mg
EUR 131
Description: ABT-263 is an orally sellecitive inhibitor of B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. ABT-263 is a small molecular with the formula of C47H55ClF3N5O6S3 and Molecular Weight of 974.

ABT-263 (Navitoclax)

A3007-100 100 mg
EUR 456
Description: ABT-263 is an orally sellecitive inhibitor of B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. ABT-263 is a small molecular with the formula of C47H55ClF3N5O6S3 and Molecular Weight of 974.

ABT-263 (Navitoclax)

A3007-1000 1 g
EUR 3298
Description: ABT-263 is an orally sellecitive inhibitor of B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. ABT-263 is a small molecular with the formula of C47H55ClF3N5O6S3 and Molecular Weight of 974.

ABT-263 (Navitoclax)

A3007-5 5 mg
EUR 108
Description: ABT-263 is an orally sellecitive inhibitor of B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. ABT-263 is a small molecular with the formula of C47H55ClF3N5O6S3 and Molecular Weight of 974.

ABT-263 (Navitoclax)

A3007-5.1 10 mM (in 1mL DMSO)
EUR 166
Description: ABT-263 is an orally sellecitive inhibitor of B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. ABT-263 is a small molecular with the formula of C47H55ClF3N5O6S3 and Molecular Weight of 974.

ABT-263 (Navitoclax)

A3007-50 50 mg
EUR 282
Description: ABT-263 is an orally sellecitive inhibitor of B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. ABT-263 is a small molecular with the formula of C47H55ClF3N5O6S3 and Molecular Weight of 974.

ABT-263 (Navitoclax)

A3007-S Evaluation Sample
EUR 81
Description: ABT-263 is an orally sellecitive inhibitor of B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. ABT-263 is a small molecular with the formula of C47H55ClF3N5O6S3 and Molecular Weight of 974.

ABT-751 (E7010)

A1493-10 10 mg
EUR 148
Description: ABT-751(E 7010) is a novel bioavailable tubulin-binding and antimitotic agent [1][2].Microtubules are major structure of cells.

ABT-751 (E7010)

A1493-100 100 mg
EUR 595
Description: ABT-751(E 7010) is a novel bioavailable tubulin-binding and antimitotic agent [1][2].Microtubules are major structure of cells.

ABT-751 (E7010)

A1493-5.1 10 mM (in 1mL DMSO)
EUR 177
Description: ABT-751(E 7010) is a novel bioavailable tubulin-binding and antimitotic agent [1][2].Microtubules are major structure of cells.

ABT-751 (E7010)

A1493-50 50 mg
EUR 432
Description: ABT-751(E 7010) is a novel bioavailable tubulin-binding and antimitotic agent [1][2].Microtubules are major structure of cells.

EZSolution?ABT-494 (Upadacitinib)

B2486-5
EUR 272

Zinc Finger Protein 737 (ZNF737) Antibody

abx030856-400ul 400 ul
EUR 523
  • Shipped within 5-10 working days.

Zinc Finger Protein 737 (ZNF737) Antibody

abx030856-80l 80 µl
EUR 286
  • Shipped within 5-10 working days.

BCl-2 Inhibitor, ABT-199

2253-1
EUR 147

BCl-2 Inhibitor, ABT-199

2253-5
EUR 311

Recombinant (Sf9) Human Phosphoinositide 3-kinase p110g inactive mutant

RP-737 1 ug
EUR 286

Human Zinc finger protein 737, ZNF737 ELISA KIT

ELI-44407h 96 Tests
EUR 824

Recombinant Caenorhabditis Elegans R05D3.2 Protein (aa 1-737)

VAng-Ly3607-inquire inquire Ask for price
Description: Caenorhabditis Elegans LIMR family protein R05D3.2 (R05D3.2), partial, recombination protein.

Recombinant Mycoplasma Pneumoniae MPN_370 Protein (aa 1-737)

VAng-Lsx04929-inquire inquire Ask for price
Description: Mycoplasma Pneumoniae (strain ATCC 29342 / M129) Putative adhesin P1-like protein MPN_370, recombinant protein.

Recombinant Streptococcus Pneumoniae pnp Protein (aa 1-737)

VAng-Ly1222-inquire inquire Ask for price
Description: Streptococcus Pneumoniae Polyribonucleotide nucleotidyltransferase, partial, recombinant protein.

Recombinant Schizosaccharomyces Pombe SPBC16H5.12c Protein (aa 1-737)

VAng-Yyj6177-inquire inquire Ask for price
Description: Schizosaccharomyces Pombe (strain 972 / ATCC 24843) (Fission yeast) Uncharacterized protein C16H5.12c (SPBC16H5.12c), recombinant protein.

Recombinant Mycobacterium Vanbaalenii katG2 Protein (aa 1-737)

VAng-Yyj5075-inquire inquire Ask for price
Description: Mycobacterium Vanbaalenii (strain DSM 7251 / PYR-1) Catalase-peroxidase 2 (katG2), recombinant protein.

Recombinant Mycobacterium Bovis recG Protein (aa 1-737)

VAng-Yyj3541-inquire inquire Ask for price
Description: Mycobacterium Bovis ATP-dependent DNA helicase recG (recG), recombinant protein.

Anti-EGFR (ABT-806)-Mc-MMAF ADC

ADC-W-515 1mg Ask for price
Description: This ADC product is comprised of an anti-EGFR monoclonal antibody (ABT-806) conjugated via a MC linker to MMAF

Recombinant Streptococcus Pneumoniae pnp Protein (aa 1-737) (strain JJA)

VAng-Ly1675-inquire inquire Ask for price
Description: Streptococcus Pneumoniae (strain JJA) Polyribonucleotide nucleotidyltransferase, partial, recombinant protein.

ABT 737